Stanford phd candidate Calvin schmidt posts about investing opportunities in synthetic biology. Available for consulting on potential investments in this area.

Calvin Schmidt Synthetic Biology Index: August Update

Performance overview
Value at beginning of month: $101,916.25
Value at end of month: $97,956.98
Month over month change: -3.88%
Total CAGR: -3.11%

Related indices, monthly change
NASDAQ: -1.83%
IVV (iShares Core S&P 500): -1.10%
IBB (iShares NASDAQ Biotechnology Index): -2.73%
MXI (iShares Global Materials): +1.77%
VEGI (iShares MSCI Global Agriculture Producers): -1.32%
ICLN (iShares Clean Energy): +1.67%

Individual performances


The index fell to new lows, reaching a record low during this month before gaining a few percent in the last week. Amyris, BioAmber, and TerraVia all lost over 40%, but Intrexon was the main driver behind the down month, dropping over 20%.

Changes made to index

Added Calyxt, Dyadic International, and Kraig Biocraft Laboratories and dropped TerraVia Holdings

Allocation as of July 28, 2017


Calvin Schmidt Synthetic Biology Index: September Update

Calvin Schmidt Synthetic Biology Index: July Update